Skip to content
My WebMD Sign In, Sign Up

Cancer Health Center

Font Size
A
A
A

'iKnife' Tells Surgeon Whether Tissue Is Cancerous

But more research needed to see if device works in everyday practice, expert says

WebMD News from HealthDay

Arrival of new residents and fellows at hospitals

By Dennis Thompson

HealthDay Reporter

WEDNESDAY, July 17 (HealthDay News) -- An experimental surgical "knife" can accurately identify cancerous tissue as a surgeon cuts through it, creating the potential for shorter cancer surgeries that remove all traces of tumor, according to a study co-written by the device's developers.

The "iKnife" uses electricity to cauterize surgical incisions as they are made, and then samples the resulting smoke to determine whether the tissue being cut is healthy or cancerous.

The iKnife accurately identified cancerous and healthy tissue 97 percent of the time in recent human trials, according to the study published July 17 in the journal Science Translational Medicine.

However, one cancer expert said it's too soon to tell if the device will make a difference in real-world practice and whether it would be worth the hefty cost.

The new technology analyzes the smoke from cauterized incisions and compares the results to a database of nearly 3,000 tissue-specific "signatures."

It can be difficult for cancer surgeons to tell if they've completely removed a tumor. They currently must send tissue samples to a pathologist and then wait 20 to 30 minutes -- with the patient still under anesthesia -- to see if they have successfully removed all cancer cells, according to background information in the study.

By comparison, diagnosis using the iKnife takes up to three seconds, said study co-author Zoltan Takats, a researcher with computational and systems medicine in the department of surgery and cancer at Imperial College London.

"We believe using this technology, since there is no waiting time, can significantly reduce the amount of time the patient spends in the operating theater," Takats said. "We also can hopefully decrease the local tumor recurrence rate, which in cases like breast cancer can be as high as 30 percent."

Researchers developed and tested the technology with funding from the European Research Council and the National Institute for Health Research in Great Britain, Takats said. They have since formed a company, MediMass, funded by venture capital to further develop and market the iKnife.

The trials reported in the new study involved 81 patients undergoing cancer surgery at three Hungarian hospitals. The iKnife's readings were compared to post-surgery analysis of the same tissue samples to determine the device's accuracy.

Capital equipment costs for the iKnife will be more than $380,000 per unit, said Jeremy Nicholson, a co-researcher of Takats' at Imperial College London.

However, the researchers contend that the iKnife ultimately could save money by allowing hospitals to downsize their pathology departments and by reducing staff time spent in surgery.

"The cost per patient will probably be quite small in comparison with the overall patient journey, and if the patient treatment is better with lower cancer recurrence then there is a very large saving to the health service," Nicholson said.

Today on WebMD

Building a Support System
Blog
cancer fighting foods
SLIDESHOW
 
precancerous lesions slideshow
SLIDESHOW
quit smoking tips
SLIDESHOW
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article